[Answered] Designers are the driving force in the retail business model in the fashion industry. a. True a. ...

This topic contains a solution. Click here to go to the answer

Author Question: Designers are the driving force in the retail business model in the fashion industry. a. True a. ... (Read 67 times)

ETearle

Hero Member
Posts: 580

on: Sep 11, 2018

Designers are the driving force in the retail business model in the fashion industry.

a. True
a. False

Question 2

A business strategy is concerned with competing in the marketplace.

a. True
b. False

Need homework help now?

Ask unlimited questions for free

Ask a Question

Marked as best answer by a Subject Expert

fauacakatahaias

Sr. Member
Posts: 353

Reply #1 on: Sep 11, 2018

Answer to Question 1

b The consumer is the driving force in the retail business model in the fashion industry.

Answer to Question 2

a

ETearle

Member
Posts: 580

Reply 2 on: Sep 11, 2018

Wow, this really help

frankwu0507

Member
Posts: 322

Reply 3 on: Yesterday

Excellent

« previous next »

Did you know?

Addicts to opiates often avoid treatment because they are afraid of withdrawal. Though unpleasant, with proper management, withdrawal is rarely fatal and passes relatively quickly.

Did you know?

Illness; diuretics; laxative abuse; hot weather; exercise; sweating; caffeine; alcoholic beverages; starvation diets; inadequate carbohydrate consumption; and diets high in protein, salt, or fiber can cause people to become dehydrated.

Did you know?

The average person is easily confused by the terms pharmaceutics and pharmacology, thinking they are one and the same. Whereas pharmaceutics is the science of preparing and dispensing drugs (otherwise known as the science of pharmacy), pharmacology is the study of medications.

Did you know?

Patients who cannot swallow may receive nutrition via a parenteral route—usually, a catheter is inserted through the chest into a large vein going into the heart.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.